title: Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII.
abstract: The transmembrane protein tissue factor (TF) is the cell surface receptor for coagulation factor VII (FVII) and activated factor VII (FVIIa). Recently, TF has been identified as a regulator of angiogenesis, tumor growth, and metastasis. This study was designed to link the binding of FVII(a) to its receptor, TF, with the subsequent triggering of angiogenesis through vascular endothelial growth factor (VEGF) production by human lung fibroblasts. We report that incubation of fibroblasts, which express constitutive surface TF, with FVII(a) induces VEGF synthesis. FVII(a)-induced VEGF secretion, assessed by a specific enzyme-linked immunosorbent assay, was time- and concentration-dependent. VEGF secretion was maximal after 24 hours of incubation of the cells with 100 nmol/L FVII(a) and represented a threefold induction of the basal VEGF level. Reverse transcriptase-polymerase chain reaction analysis of VEGF detected three mRNA species of 180, 312, and 384 bp corresponding, respectively, to VEGF121, VEGF165, and VEGF189. A 2.5- to 3.5-fold increase was observed for the 180- and 312-bp transcripts at 12 and 24 hours, respectively. FVII(a)-dependent VEGF production was inhibited by a pool of antibodies against TF, pointing to the involvement of this receptor. On specific active-site inhibition with dansyl-glutamyl-glycinyl-arginyl chloromethyl ketone, FVIIa lost 70% of its capacity to elicit VEGF production. Consistent with this, the native form (zymogen) of FVII only had a 1.8-fold stimulating effect. Protein tyrosine kinase and protein kinase C are involved in signal transduction leading to VEGF production, as shown by the inhibitory effects of genistein and GF 109203X. The results of this study indicate that TF is essential for VIIa-induced VEGF production by human fibroblasts and that its role is mainly linked to the proteolytic activity of the TF-VIIa complex.
authors.affiliation: INSERM U479 and Service d'Hématologie et d'Immunologie, CHU Xavier Bichat, Paris, France.
authors.forename: V
authors.initials: V
authors.lastname: Ollivier
authors.forename: S
authors.initials: S
authors.lastname: Bentolila
authors.forename: J
authors.initials: J
authors.lastname: Chabbat
authors.forename: J
authors.initials: J
authors.lastname: Hakim
authors.forename: D
authors.initials: D
authors.lastname: de Prost
mesh_terms: D002478:Cells, Cultured; D016228:Endothelial Growth Factors / Q000096:biosynthesis*; D015942:Factor VIIa / Q000378:metabolism / Q000494:pharmacology*; D005347:Fibroblasts / Q000378:metabolism; D006801:Humans; D008222:Lymphokines / Q000096:biosynthesis*; D018919:Neovascularization, Physiologic; D015398:Signal Transduction / Q000187:drug effects; D013925:Thromboplastin / Q000378:metabolism*; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
chemical_list: D016228:Endothelial Growth Factors; D008222:Lymphokines; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D013925:Thromboplastin; D015942:Factor VIIa